文献速递肝肾功能剂量调整特殊人群用药药物相互作用

艾瑞昔布临床药代动力学与体内处置

Clinical Pharmacokinetics and Disposition of Imrecoxib.
PubMed 文献 · Clin Pharmacokinet · 2026-09-17

本叙述性综述评估艾瑞昔布的临床药代动力学,涵盖体内处置、特殊人群、药物相互作用及剂量调整证据。该药口服后2-3小时达峰,食物增加全身暴露,经CYP3A4/CYP2D6及醛氧化酶代谢为活性产物M1和M2。重度肾功能不全时M2暴露显著升高,中度肝功能不全时艾瑞昔布与M1暴露大幅升高,目前尚无确定性剂量调整推荐。

要点

  • 食物增加艾瑞昔布全身暴露,口服后2-3小时达血浆峰浓度。
  • 氟康唑使艾瑞昔布Cₘₐₓ和AUC0-t分别升高约88%和72%。
  • 重度肾功能不全可考虑减量,但不支持常规按年龄调整剂量。

核心结论

  • 目前尚无确定性剂量调整推荐;重度肾功能不全可考虑减量,肝功能不全最佳方案未定义。
  • 多剂量艾瑞昔布未显著改变华法林药代动力学或抗凝反应。
  • 不支持常规按年龄调整剂量。

研究设计与样本

  • 叙述性综述,评估艾瑞昔布的临床药代动力学、体内处置、特殊人群、药物相互作用与剂量调整证据。
  • 证据主要来自小样本、多为单次给药的研究,人群以中国人为主。

主要发现

  • 口服后2-3小时达血浆峰浓度,食物增加全身暴露;蛋白结合率高,经CYP3A4和CYP2D6介导生成M1,M2生成还涉及醛氧化酶。
  • M1和M2均有药理活性,M2为主要循环代谢物;原形药尿排泄可忽略,M1、M2及其结合物参与肾排泄。
  • 重度肾功能不全使M2的AUC0-t约为肾功能正常者的3.7倍,表观清除率降至约37%。
  • 中度肝功能不全使艾瑞昔布和M1的AUC0-∞分别约为匹配健康者的10.8倍和3.2倍,M2的AUC0-∞增加约35%。
  • 小样本单次给药研究中,老年受试者艾瑞昔布、M1、M2暴露数值更高但差异无统计学意义,未证明药代动力学等效。

关键数值与推荐

  • 重度肾功能不全:M2的AUC0-t约为肾功能正常者的3.7倍,表观清除率约为正常者的37%。
  • 中度肝功能不全:艾瑞昔布AUC0-∞约为匹配健康者的10.8倍,M1约为3.2倍,M2增加约35%。
  • 氟康唑使艾瑞昔布Cₘₐₓ和AUC0-t分别升高约88%和72%,M1、M2暴露无相应增加。
  • 口服后2-3小时达峰;多剂量艾瑞昔布未显著改变华法林药代动力学或抗凝反应。

临床怎么用

  • 重度肾功能不全者可考虑减量,但暴露-反应后果与减量方案尚未验证。
  • 合并强CYP3A4抑制剂如氟康唑时注意艾瑞昔布暴露升高。
  • 肝功能不全最佳给药方案未定义,需个体化评估。

局限性

  • 证据受限于小样本、多为单次给药的研究。
  • 研究人群以中国人为主。
  • 缺乏整合艾瑞昔布、M1和M2的经过验证的暴露-反应关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imrecoxib is a cyclooxygenase-2-preferential nonsteroidal anti-inflammatory drug approved in China for the symptomatic treatment of osteoarthritis and is currently marketed only in China. This narrative review evaluates its clinical pharmacokinetics, including disposition, special populations, drug-drug interactions, and evidence for dose adjustment. After oral administration, imrecoxib reaches peak plasma concentrations within 2-3 h, and food increases systemic exposure. It is highly protein bound and extensively metabolised sequentially from imrecoxib (M0) to 4'-hydroxymethylimrecoxib (M1), then to the aldehyde intermediate 4'-formylimrecoxib (M-CHO), and finally to 4'-carboxyimrecoxib (M2). Cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2D6 (CYP2D6) mediate M1 formation, while M2 formation also involves aldehyde oxidase. Both M1 and M2 are pharmacologically active, and M2 is the predominant circulating metabolite. Unchanged urinary excretion is negligible, whereas M1, M2, and their conjugates contribute to renal elimination. Severe renal impairment markedly increases M2 exposure (area under the plasma concentration-time curve from time zero to the last measurable concentration [AUC0-t] approximately 3.7-fold that in subjects with normal renal function) and reduces its apparent clearance to approximately 37% of that in subjects with normal renal function, although the clinical exposure-response consequences and the proposed reduced-dose regimens remain unvalidated. Moderate hepatic impairment markedly increases imrecoxib and M1 exposure (area under the plasma concentration-time curve from time zero to infinity [AUC0-∞] approximately 10.8-fold and 3.2-fold that in matched healthy subjects, respectively), while M2 AUC0-∞ increases by approximately 35%. In a small single-dose study, exposure to imrecoxib, M1, and M2 was numerically higher in older subjects, but the differences were not statistically significant and pharmacokinetic equivalence was not demonstrated. Currently, no definitive dose-adjustment recommendations have been established, although dose reduction may be considered in severe renal impairment; routine age-based adjustment is not supported, and the optimal regimen in hepatic impairment remains undefined. Multiple-dose imrecoxib did not meaningfully alter warfarin pharmacokinetics or anticoagulant response, whereas fluconazole increased imrecoxib maximum plasma concentration (Cₘₐₓ) and AUC0-t by approximately 88% and 72%, respectively, without comparable increases in M1 or M2 exposure. Current evidence is limited by small, mainly single-dose studies, predominantly Chinese populations, and the absence of validated exposure-response relationships integrating imrecoxib, M1, and M2. More robust studies are needed to define dose adjustment in organ impairment.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Zhao S, Li C, Mallillin MC, et al. Clinical Pharmacokinetics and Disposition of Imrecoxib. Clin Pharmacokinet. 2026. PMID: 42754736. doi:10.1007/s40262-026-01705-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。